These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1649765)

  • 41. Modification of the radiation response of the mouse kidney by misonidazole and WR-2721.
    Williams MV; Denekamp J
    Int J Radiat Oncol Biol Phys; 1983 Nov; 9(11):1731-6. PubMed ID: 6315650
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution.
    Rasey JS; Nelson NJ; Mahler P; Anderson K; Krohn KA; Menard T
    Radiat Res; 1984 Mar; 97(3):598-607. PubMed ID: 6328565
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A new orally active, aminothiol radioprotector-free of nausea and hypotension side effects at its highest radioprotective doses.
    Soref CM; Hacker TA; Fahl WE
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e701-7. PubMed ID: 22330992
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Amifostine and hematologic effects.
    Sriswasdi C; Jootar S; Giles FJ
    J Med Assoc Thai; 2000 Apr; 83(4):374-82. PubMed ID: 10808697
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Amifostine: the first selective-target and broad-spectrum radioprotector.
    Kouvaris JR; Kouloulias VE; Vlahos LJ
    Oncologist; 2007 Jun; 12(6):738-47. PubMed ID: 17602063
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radioprotective effect of Ocimum sanctum and amifostine on the salivary gland of rats after therapeutic radioiodine exposure.
    Joseph LJ; Bhartiya US; Raut YS; Hawaldar RW; Nayak Y; Pawar YP; Jambhekar NA; Rajan MG
    Cancer Biother Radiopharm; 2011 Dec; 26(6):737-43. PubMed ID: 22087607
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dephosphorylation of WR-2721 with mouse tissue homogenates.
    Mori T; Nikaido O; Sugahara T
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1529-31. PubMed ID: 6090356
    [TBL] [Abstract][Full Text] [Related]  

  • 48. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
    Souid AK; Fahey RC; Dubowy RL; Newton GL; Bernstein ML
    Cancer Chemother Pharmacol; 1999; 44(6):498-504. PubMed ID: 10550571
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PREVENTION OF RADIATION-INDUCED RETINOPATHY WITH AMIFOSTINE IN WISTAR ALBINO RATS.
    Akkus Yildirim B; Çetin E; Topkan E; Ozyigit G; Cengiz M; Surucu S; Usubutun A; Akyol F
    Retina; 2015 Jul; 35(7):1458-64. PubMed ID: 25768249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects.
    Peters GJ; van der Vijgh WJ
    Eur J Cancer; 1995; 31A Suppl 1():S1-7. PubMed ID: 7577093
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Binding of aminoalkylphosphorothioate radioprotective drugs to rodent tissue proteins.
    Livesey JC; Grunbaum Z; Krohn KA
    Biochem Pharmacol; 1990 Jun; 39(11):1807-12. PubMed ID: 2160821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bioavailability and newer methods of delivery of phosphorothioate radioprotectors.
    Fleckenstein L; Swynnerton NF; Ludden TM; Mangold DJ
    Pharmacol Ther; 1988; 39(1-3):203-12. PubMed ID: 2849124
    [No Abstract]   [Full Text] [Related]  

  • 53. Influence of chlorpromazine, bleomycin and WR-2721 singly or in combination on the formation of radiation-induced micronuclei in mice bone marrow.
    Jagetia GC
    Strahlenther Onkol; 1994 Nov; 170(11):648-53. PubMed ID: 7526477
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.
    Yuhas JM
    Cancer Res; 1980 May; 40(5):1519-24. PubMed ID: 6245795
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy].
    Wrembel-Wargocka J; Jabłońska H; Chomiczewski K
    Przegl Lek; 1996; 53(11):820-5. PubMed ID: 9173447
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse1,2.
    Utley JF; Marlowe C; Waddell WJ
    Radiat Res; 1976 Nov; 68(2):284-91. PubMed ID: 185642
    [No Abstract]   [Full Text] [Related]  

  • 57. A risk-benefit assessment of amifostine in cytoprotection.
    Mabro M; Faivre S; Raymond E
    Drug Saf; 1999 Nov; 21(5):367-87. PubMed ID: 10554052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action.
    Grdina DJ; Shigematsu N; Dale P; Newton GL; Aguilera JA; Fahey RC
    Carcinogenesis; 1995 Apr; 16(4):767-74. PubMed ID: 7728953
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase-separation inhibitors and prevention of selenite cataract.
    Clark JI; Steele JE
    Proc Natl Acad Sci U S A; 1992 Mar; 89(5):1720-4. PubMed ID: 1311849
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clearance of S-(3-amino-2-hydroxypropyl) phosphorothioate (WR-77913) in rats.
    Lam TT; Liu D; Brody MA; Chu R; Tso MO
    Exp Eye Res; 1991 Jun; 52(6):661-7. PubMed ID: 1649765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.